Tags

Type your tag names separated by a space and hit enter

Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Circulation. 2006 Aug 29; 114(9):974-84.Circ

Authors+Show Affiliations

Obesity Clinical Trials Program, Box 3292, Duke University Medical Center, Durham, NC 27710, USA. gadde001@mc.duke.eduNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16940206

Citation

Gadde, Kishore M., and David B. Allison. "Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks." Circulation, vol. 114, no. 9, 2006, pp. 974-84.
Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006;114(9):974-84.
Gadde, K. M., & Allison, D. B. (2006). Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation, 114(9), 974-84.
Gadde KM, Allison DB. Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks. Circulation. 2006 Aug 29;114(9):974-84. PubMed PMID: 16940206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. AU - Gadde,Kishore M, AU - Allison,David B, PY - 2006/8/31/pubmed PY - 2006/9/19/medline PY - 2006/8/31/entrez SP - 974 EP - 84 JF - Circulation JO - Circulation VL - 114 IS - 9 SN - 1524-4539 UR - https://www.unboundmedicine.com/medline/citation/16940206/Cannabinoid_1_receptor_antagonist_rimonabant_for_management_of_obesity_and_related_risks_ L2 - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.105.596130?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -